AUTHORS

Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

The Economy, Politics, and Your Portfolio

There's huge potential for a spike in volatility.

Real Opportunities in Real Estate Continue to Pop Up

Beazer Homes USA and JBG Smith Properties are two names that are worth looks in the real estate sector.

Here Are 2 Small Biotech Names Where I'm Using My Simple Covered Call Strategy

Let's dig into Strongbridge Biopharma and Agenus.

2 Stocks for the Surging Single-Family Housing Market

I continue to believe that smaller cities will be huge winners in coming years as technology enables virtual work forces.

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.

3 Diverse Companies With Recent Insider Buying in Common

Chatham Lodging Trust, Summit Materials and Vistra Corp. all have seen their CEOs add to their holdings in these companies.

2 Small Biotechs That Have Attracted My Attention and My Cash

BioXcel Therapeutics and Avadel Pharmaceuticals are new additions to my personal portfolio based on their promising drug prospects.

Just Another Wild Day on the Small-Cap Biotech Rollercoaster

Use long-dated calls to take some of risk out of this inherently high-beta space.

Matching Downside Protection With Upside Potential in Akebia Therapeutics

This covered call strategy is an effective way to navigate an overbought market.

2 Candidates to Consider as Biotech Buyout Activity Picks Up

A handful of deals have been announced this week alone and they give rise to expectations of more acquisitions to come.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight